BACKGROUND: Renal tubular epithelial cells (TECs) play an active role in renal inflammation. Previous studies have demonstrated the capacity of TECs to modulate T-cell responses both positively and negatively. Recently, new costimulatory molecules [inducible T cell costimulator-L (ICOS-L) and B7-H1] have been described, which appear to be involved in peripheral T-cell activation. METHODS: We characterized expression and regulation of costimulatory molecules on primary human TECs and the TEC line human kidney-2 (HK-2) with reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry. Immunohistochemistry was performed on human kidney biopsies. The capacity of TECs to modulate T-cell activation was studied in TEC/T-cell cultures. RESULTS: We demonstrate that TECs express ICOS-L and B7-H1 in vitro and in vivo. Stimulation with interferon-gamma (IFN-gamma) resulted in increased expression of B7-H1, whereas ICOS-L expression was marginally increased upon stimulation with CD40L, with no effect of interleukin (IL-1), IL-17, or tumor necrosis factor-alpha (TNF-alpha). Furthermore, we show that TECs are able to costimulate T cells that have received signal-1 using alphaCD3 antibodies, inducing strong IL-10 production, which was partially mediated by ICOS-L. In contrast, B7-H1 appeared to be involved in inhibition of proliferation and cytokine synthesis. In addition, TECs were able to alter the cytokine profile of fully activated T cells, which were incubated with alphaCD3 and alphaCD28 antibodies, resulting in low IFN-gamma and high IL-10 production. This activity appeared to be independent of ICOS-L and B7-H1. CONCLUSION: Interaction of tubular epithelial cells and kidney infiltrating T cells via ICOS-L and B7-H1 may change the balance of positive and negative signals to the T cells, leading to IL-10 production and limitation of local immune responses.
BACKGROUND: Renal tubular epithelial cells (TECs) play an active role in renal inflammation. Previous studies have demonstrated the capacity of TECs to modulate T-cell responses both positively and negatively. Recently, new costimulatory molecules [inducible T cell costimulator-L (ICOS-L) and B7-H1] have been described, which appear to be involved in peripheral T-cell activation. METHODS: We characterized expression and regulation of costimulatory molecules on primary human TECs and the TEC line human kidney-2 (HK-2) with reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry. Immunohistochemistry was performed on human kidney biopsies. The capacity of TECs to modulate T-cell activation was studied in TEC/T-cell cultures. RESULTS: We demonstrate that TECs express ICOS-L and B7-H1 in vitro and in vivo. Stimulation with interferon-gamma (IFN-gamma) resulted in increased expression of B7-H1, whereas ICOS-L expression was marginally increased upon stimulation with CD40L, with no effect of interleukin (IL-1), IL-17, or tumor necrosis factor-alpha (TNF-alpha). Furthermore, we show that TECs are able to costimulate T cells that have received signal-1 using alphaCD3 antibodies, inducing strong IL-10 production, which was partially mediated by ICOS-L. In contrast, B7-H1 appeared to be involved in inhibition of proliferation and cytokine synthesis. In addition, TECs were able to alter the cytokine profile of fully activated T cells, which were incubated with alphaCD3 and alphaCD28 antibodies, resulting in low IFN-gamma and high IL-10 production. This activity appeared to be independent of ICOS-L and B7-H1. CONCLUSION: Interaction of tubular epithelial cells and kidney infiltrating T cells via ICOS-L and B7-H1 may change the balance of positive and negative signals to the T cells, leading to IL-10 production and limitation of local immune responses.
Authors: M W H J Demmers; S S Korevaar; M Roemeling-van Rhijn; T P P van den Bosch; M J Hoogduijn; M G H Betjes; W Weimar; C C Baan; A T Rowshani Journal: Clin Exp Immunol Date: 2015-03 Impact factor: 4.330
Authors: Lino L Teichmann; Jaime L Cullen; Michael Kashgarian; Chen Dong; Joe Craft; Mark J Shlomchik Journal: Immunity Date: 2015-03-17 Impact factor: 31.745
Authors: K Iwasaki; H Hamana; H Kishi; T Yamamoto; T Hiramitsu; M Okad; T Tomosugi; A Takeda; S Narumi; Y Watarai; Y Miwa; M Okumura; Y Matsuoka; K Horimi; A Muraguchi; T Kobayash Journal: Clin Exp Immunol Date: 2020-07-18 Impact factor: 4.330
Authors: Hao Li; Maria G Tsokos; Rhea Bhargava; Iannis E Adamopoulos; Hanni Menn-Josephy; Isaac E Stillman; Philip Rosenstiel; Jarrat Jordan; George C Tsokos Journal: J Clin Invest Date: 2021-06-15 Impact factor: 14.808
Authors: Qiang Zhang; Mir Munir A Rahim; David S J Allan; Megan M Tu; Simon Belanger; Elias Abou-Samra; Jaehun Ma; Harman S Sekhon; Todd Fairhead; Haggag S Zein; James R Carlyle; Stephen K Anderson; Andrew P Makrigiannis Journal: PLoS One Date: 2012-12-04 Impact factor: 3.240